Chimerix
anti preclinical activity that is a viral inhibitor replicating | Chimerix
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
37 of 41
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
August 2023
anti preclinical activity that is a viral inhibitor efficacy in mouse adapted model viral lung titer across multiple million grant to fund formulations that could enable oral administration with improved lung delivery inhaled liquid aerosol formulation minimal systemic exposure replicating hours post infection | Chimerix
Investor Presentation
March 2023
anti preclinical activity that is a viral inhibitor replicating | Chimerix
Related slides by other companies
AstraZeneca
ESG
March 2023
healthy heart | AstraZeneca
HeartBeam
Results
August 2023
activities closed a secondary offering of million followed by registered direct offering of million for a total of million public ventures acted as placement agent for the offering the funding will enable to execute on upcoming product development clinical and regulatory milestones extending the cash runway into late | HeartBeam
Nuvalent
IPO
July 2021
| Nuvalent
Nuvalent
IPO
July 2021
preclinical activity against | Nuvalent
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights